Literature DB >> 26012842

Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine.

N Chatain1, R C Perera2, G Rossetti2,3, J Rossa1, P Carloni2, M Schemionek1, T Haferlach4, T H Brümmendorf1, S Schnittger4, S Koschmieder1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26012842     DOI： 10.1038/leu.2015.131

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.

Authors:  Jennifer L Rocnik; Rachel Okabe; Jin-Chen Yu; Benjamin H Lee; Neill Giese; David P Schenkein; D Gary Gilliland
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

2.  Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

Authors:  Stefan Fröhling; Claudia Scholl; Ross L Levine; Marc Loriaux; Titus J Boggon; Olivier A Bernard; Roland Berger; Hartmut Döhner; Konstanze Döhner; Benjamin L Ebert; Sewit Teckie; Todd R Golub; Jingrui Jiang; Marcus M Schittenhelm; Benjamin H Lee; James D Griffin; Richard M Stone; Michael C Heinrich; Michael W Deininger; Brian J Druker; D Gary Gilliland
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

3.  Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells.

Authors:  H J McKenna; K L Stocking; R E Miller; K Brasel; T De Smedt; E Maraskovsky; C R Maliszewski; D H Lynch; J Smith; B Pulendran; E R Roux; M Teepe; S D Lyman; J J Peschon
Journal:  Blood       Date:  2000-06-01       Impact factor: 22.113

4.  Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice.

Authors:  Li Li; Emily Bailey; Sarah Greenblatt; David Huso; Donald Small
Journal:  Blood       Date:  2011-09-08       Impact factor: 22.113

5.  Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.

Authors:  Hitoshi Kiyoi; Ryuzo Ohno; Ryuzo Ueda; Hidehiko Saito; Tomoki Naoe
Journal:  Oncogene       Date:  2002-04-11       Impact factor: 9.867

6.  Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

Authors:  Sabine Kayser; Richard F Schlenk; Martina Correa Londono; Frank Breitenbuecher; Kerstin Wittke; Juan Du; Silja Groner; Daniela Späth; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Thomas Fischer; Konstanze Döhner
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

7.  Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.

Authors:  Mohamed Rahmani; Mandy Mayo Aust; Elisa Attkisson; David C Williams; Andrea Ferreira-Gonzalez; Steven Grant
Journal:  Cancer Res       Date:  2012-12-12       Impact factor: 12.701

8.  Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes.

Authors:  Chunaram Choudhary; Jesper V Olsen; Christian Brandts; Jürgen Cox; Pavankumar N G Reddy; Frank D Böhmer; Volker Gerke; Dirk-E Schmidt-Arras; Wolfgang E Berdel; Carsten Müller-Tidow; Matthias Mann; Hubert Serve
Journal:  Mol Cell       Date:  2009-10-23       Impact factor: 17.970

9.  Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors.

Authors:  K Mackarehtschian; J D Hardin; K A Moore; S Boast; S P Goff; I R Lemischka
Journal:  Immunity       Date:  1995-07       Impact factor: 31.745

10.  Deletion and deletion/insertion mutations in the juxtamembrane domain of the FLT3 gene in adult acute myeloid leukemia.

Authors:  Kristin K Deeb; Matthew T Smonskey; HanChun DeFedericis; George Deeb; Sheila N J Sait; Meir Wetzler; Eunice S Wang; Petr Starostik
Journal:  Leuk Res Rep       Date:  2014-10-16
View more
  10 in total

Review 1.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

2.  Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

Authors:  Silvia Maifrede; Margaret Nieborowska-Skorska; Katherine Sullivan-Reed; Yashodhara Dasgupta; Paulina Podszywalow-Bartnicka; Bac Viet Le; Martyna Solecka; Zhaorui Lian; Elizaveta A Belyaeva; Alina Nersesyan; Marcin M Machnicki; Monika Toma; Nicolas Chatain; Malgorzata Rydzanicz; Huaqing Zhao; Jaroslav Jelinek; Katarzyna Piwocka; Tomasz Sliwinski; Tomasz Stoklosa; Rafal Ploski; Thomas Fischer; Stephen M Sykes; Steffen Koschmieder; Lars Bullinger; Peter Valent; Mariusz A Wasik; Jian Huang; Tomasz Skorski
Journal:  Blood       Date:  2018-05-21       Impact factor: 22.113

3.  Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis.

Authors:  David J Young; Bao Nguyen; Ruiqi Zhu; Jaesung Seo; Li Li; Mark J Levis; Keith W Pratz; Amy S Duffield; Donald Small
Journal:  Blood Adv       Date:  2021-05-11

4.  Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia.

Authors:  Masahiro Sakaguchi; Hiroki Yamaguchi; Marika Kuboyama; Yuho Najima; Kensuke Usuki; Toshimitsu Ueki; Iekuni Oh; Shinichiro Mori; Eri Kawata; Nobuhiko Uoshima; Yutaka Kobayashi; Shinichi Kako; Kenji Tajika; Katsuhiro Shono; Kensuke Kayamori; Masao Hagihara; Junya Kanda; Hitoji Uchiyama; Junya Kuroda; Naoyuki Uchida; Yasushi Kubota; Shinya Kimura; Saiko Kurosawa; Kenta Date; Nana Nakajima; Atsushi Marumo; Ikuko Omori; Yusuke Fujiwara; Kazuki Terada; Shunsuke Yui; Satoshi Wakita; Kunihito Arai; Tomoaki Kitano; Kazuhiko Kakihana; Yoshinobu Kanda; Kazuteru Ohashi; Takahiro Fukuda; Koiti Inokuchi
Journal:  Int J Hematol       Date:  2019-08-20       Impact factor: 2.490

5.  Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.

Authors:  Lijuan Han; Claudia Schubert; Johanna Köhler; Mirle Schemionek; Susanne Isfort; Tim H Brümmendorf; Steffen Koschmieder; Nicolas Chatain
Journal:  J Hematol Oncol       Date:  2016-05-13       Impact factor: 17.388

6.  The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor.

Authors:  Nadine Sandhöfer; Julia Bauer; Katrin Reiter; Annika Dufour; Maja Rothenberg; Nikola P Konstandin; Evelyn Zellmeier; Belay Tizazu; Philipp A Greif; Klaus H Metzeler; Wolfgang Hiddemann; Harald Polzer; Karsten Spiekermann
Journal:  Sci Rep       Date:  2016-06-27       Impact factor: 4.379

7.  Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis.

Authors:  Rong He; Daniel J Devine; Zheng Jin Tu; Ming Mai; Dong Chen; Phuong L Nguyen; Jennifer L Oliveira; James D Hoyer; Kaaren K Reichard; Paul L Ollila; Aref Al-Kali; Ayalew Tefferi; Kebede H Begna; Mrinal M Patnaik; Hassan Alkhateeb; David S Viswanatha
Journal:  Mod Pathol       Date:  2019-08-30       Impact factor: 7.842

Review 8.  Potential targeting of FLT3 acute myeloid leukemia.

Authors:  Alexander J Ambinder; Mark Levis
Journal:  Haematologica       Date:  2021-03-01       Impact factor: 9.941

9.  Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD.

Authors:  Sebastian Stasik; Michael Kramer; Sven Zukunft; Christoph Röllig; Claudia D Baldus; Uwe Platzbecker; Hubert Serve; Carsten Müller-Tidow; Kerstin Schäfer-Eckart; Martin Kaufmann; Stefan Krause; Tim Sauer; Mathias Hänel; Andreas Neubauer; Gerhard Ehninger; Martin Bornhäuser; Johannes Schetelig; Jan M Middeke; Christian Thiede
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

Review 10.  Developments and challenges of FLT3 inhibitors in acute myeloid leukemia.

Authors:  Shuai-Shuai Ge; Song-Bai Liu; Sheng-Li Xue
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.